Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Tünde Csépány"'
Autor:
Ráhel Réka Bicskó, Árpád Illés, Zsuzsanna Hevessy, Gergely Ivády, György Kerekes, Gábor Méhes, Tünde Csépány, Lajos Gergely
Publikováno v:
Hematology Reports, Vol 16, Iss 2, Pp 255-259 (2024)
The co-occurrence of myasthenia gravis (MG) and paroxysmal nocturnal hemoglobinuria (PNH) is rare; only one case has been published so far. We report a 63-year-old Caucasian female patient who was diagnosed with MG at the age of 43. Thymoma was also
Externí odkaz:
https://doaj.org/article/3b0f738b6e48473f94d254294f3580fe
Autor:
Zsófia Kokas, Dániel Sandi, Zsanett Fricska-Nagy, Judit Füvesi, Tamás Biernacki, Ágnes Köves, Ferenc Fazekas, Adrienne Jóri Birkás, Gabriella Katona, Krisztina Kovács, Dániel Milanovich, Enikő Dobos, István Kapás, Gábor Jakab, Tünde Csépány, Erzsébet Bense, Klotild Mátyás, Gábor Rum, Zoltán Szolnoki, István Deme, Zita Jobbágy, Dávid Kriston, Zsuzsanna Gerócs, Péter Diószeghy, László Bors, Adrián Varga, Levente Kerényi, Gabriella Molnár, Piroska Kristóf, Zsuzsanna Ágnes Nagy, Mária Sátori, Piroska Imre, Szilvia Péntek, Péter Klivényi, Zsigmond Tamás Kincses, László Vécsei, Krisztina Bencsik
Publikováno v:
PLoS ONE, Vol 17, Iss 3 (2022)
A patients Because of the past 3 decades’ extensive research, several disease modifying therapies became available, thus a paradigm change is multiple sclerosis care was necessary. In 2018 a therapeutic guideline was created recommending that treat
Externí odkaz:
https://doaj.org/article/b74f88ce35424d3a83206f1e4beda0ee
Autor:
Tamás Biernacki, Dániel Sandi, Judit Füvesi, Zsanett Fricska-Nagy, Tamás Zsigmond Kincses, Péter Ács, Csilla Rózsa, Enikő Dobos, Botond Cseh, László Horváth, Zsuzsanna Nagy, Attila Csányi, Krisztina Kovács, Tünde Csépány, László Vécsei, Krisztina Bencsik, on the behalf of the study investigators
Publikováno v:
PLoS ONE, Vol 17, Iss 4, p e0267346 (2022)
BackgroundFingolimod was approved and reimbursed by the healthcare provider in Hungary for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS) in 2012. The present study aimed to assess the effectiveness, safety profile, and
Externí odkaz:
https://doaj.org/article/0919da52a92641838c5b0d621a707d21
Autor:
Zsófia Hayden, Beáta Bóné, Gergely Orsi, Monika Szots, Ferenc Nagy, Tünde Csépány, Zsolt Mezei, Cecília Rajda, Diána Simon, József Najbauer, Zsolt Illes, Timea Berki
Publikováno v:
Frontiers in Neurology, Vol 12 (2021)
Background: In our previous single-center study of autoimmune encephalitis (AE) related autoantibody test results we found positivity in 60 patients out of 1,034 with suspected AE from 2012 through 2018 as part of a Hungarian nationwide program. In o
Externí odkaz:
https://doaj.org/article/050da41310b14c66ad5a2fe03bed2ebb
Autor:
Thomas Berger, Monika Adamczyk-Sowa, Tünde Csépány, Franz Fazekas, Tanja Hojs Fabjan, Dana Horáková, Alenka Horvat Ledinek, Zsolt Illes, Gisela Kobelt, Saša Šega Jazbec, Eleonóra Klímová, Fritz Leutmezer, Konrad Rejdak, Csilla Rozsa, Johann Sellner, Krzysztof Selmaj, Pavel Štouracˇ, Jarmila Szilasiová, Peter Turcˇáni, Marta Vachová, Manuela Vanecková, László Vécsei, Eva Kubala Havrdová
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 13 (2020)
At two meetings of a Central European board of multiple sclerosis (MS) experts in 2018 and 2019 factors influencing daily treatment choices in MS, especially practice guidelines, biomarkers and burden of disease, were discussed. The heterogeneity of
Externí odkaz:
https://doaj.org/article/246cb9f41dbf4f6e88edc22268ad7a97
Autor:
Thomas Berger, Monika Adamczyk-Sowa, Tünde Csépány, Franz Fazekas, Tanja Hojs Fabjan, Dana Horáková, Zsolt Illes, Eleonóra Klimová, Fritz Leutmezer, Konrad Rejdak, Csilla Rozsa, Saša Šega Jazbec, Jarmila Szilasiová, Peter Turčáni, Marta Vachová, László Vécsei, Eva Havrdová
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 11 (2018)
Multiple sclerosis (MS) experts in Europe are facing rapidly rising demands of excellence due to the increasing complexity of MS therapy and management. A central European expert board of MS experts met to identify needs and obstacles with respect to
Externí odkaz:
https://doaj.org/article/bcd06b43e9f34017bd23c1c251803f57
Autor:
Tamás Árokszállási, Eszter Balogh, Rita Orbán-Kálmándi, Máté Pásztor, Anita Árokszállási, Edit Boglárka Nagy, Ivett Belán, Zsolt May, Tünde Csépány, László Csiba, Zsuzsa Bagoly, László Oláh
Publikováno v:
Journal of Clinical Medicine; Volume 12; Issue 6; Pages: 2238
Background: Intravenous thrombolysis (IVT) improves acute ischemic stroke (AIS) outcomes, but with limited success. In addition, ethanol potentiates the effect of r-tPA in ischemia models. Methods: The effect of acute alcohol consumption on IVT outco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b4c970aedcab36b2f699b3dca242c68
https://doi.org/10.3390/jcm12062238
https://doi.org/10.3390/jcm12062238
Publikováno v:
Ideggyógyászati szemle. 74:413-424
A sclerosis multiplex (SM) jellemzően a fiatal felnőttek betegsége. Gyermekkori sclerosis multiplexről 18 éves kor alatt kezdődő megbetegedés esetén beszélhetünk, bár egyes szerzők 16 éves kor alatt szabják meg a határt. Korábban „
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c34506e86fc1deb98e40033ab0568051
https://doi.org/10.18071/isz.74.0413
https://doi.org/10.18071/isz.74.0413
Autor:
Edward De Brouwer, Thijs Becker, Lorin Werthen-Brabants, Pieter Dewulf, Dimitrios Iliadis, Cathérine Dekeyser, Guy Laureys, Bart Van Wijmeersch, Veronica Popescu, Tom Dhaene, Dirk Deschrijver, Willem Waegeman, Bernard De Baets, Michiel Stock, Dana Horakova, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Marc Girard, Alexandre Prat, Alessandra Lugaresi, Pierre Grammond, Tomas Kalincik, Raed Alroughani, Francois Grand'Maison, Olga Skibina, Murat Terzi, Jeannette Lechner-Scott, Oliver Gerlach, Samia J Khoury, Elisabetta Cartechini, Vincent Van Pesch, Maria José Sà, Bianca Weinstock-Guttman, Yolanda Blanco, Radek Ampapa, Daniele Spitaleri, Claudio Solaro, Davide Maimone, Aysun Soysal, Gerardo Iuliano, Riadh Gouider, Tamara Castillo-Triviño, José Luis Sánchez-Menoyo, Anneke van der Walt, Jiwon Oh, Eduardo Aguera-Morales, Ayse Altintas, Abdullah Al-Asmi, Koen de Gans, Yara Fragoso, Tunde Csepany, Suzanne Hodgkinson, Norma Deri, Talal Al-Harbi, Bruce Taylor, Orla Gray, Patrice Lalive, Csilla Rozsa, Chris McGuigan, Allan Kermode, Angel Pérez Sempere, Simu Mihaela, Magdolna Simo, Todd Hardy, Danny Decoo, Stella Hughes, Nikolaos Grigoriadis, Attila Sas, Norbert Vella, Yves Moreau, Liesbet Peeters
Publikováno v:
PLOS Digital Health, Vol 3, Iss 7, p e0000533 (2024)
BackgroundDisability progression is a key milestone in the disease evolution of people with multiple sclerosis (PwMS). Prediction models of the probability of disability progression have not yet reached the level of trust needed to be adopted in the
Externí odkaz:
https://doaj.org/article/c8086e53dc844308be0ea446e3a32319
Autor:
Alexis Montcuquet, Henrik Kahr Mathiesen, Tomas Kalincik, Marc Girard, Karolina Hankiewicz, Marco Onofrj, Francois Grand Maison, Raed Alroughani, Mathilde Lefort, Olivier Gout, Jeannette Lechner-Scott, Marc Debouverie, Julie Prevost, Eva Havrdova, Olivier Casez, Per Soelberg Sørensen, Pierre Duquette, Jean Pelletier, Claudio Solaro, Alessandra Lugaresi, Francesco Patti, Emmanuelle Leray, Johanna Balslev Andersen, Bassem Yamout, Céline Labeyrie, Karen Schreiber, Eric Thouvenot, Nils Koch-Henriksen, Michael Broksgaard Jensen, Elisabeth Maillart, Chantal Nifle, Stephan Bramow, Pierre Clavelou, Bruno Stankoff, Olivier Heinzlef, Finn Sellebjerg, Abir Wahab, Mark Slee, Gilles Defer, Pierre Labauge, Melinda Magyari, Steve Vucic, Guillermo Izquierdo, Helmut Butzkueven, Peter Vestergaard Rasmussen, Bertrand Bourre, Maria Trojano, Franco Granella, Corinne Pottier, Jette L. Frederiksen, Olga Skibina, Recai Turkoglu, Ivania Patry, Pierre Grammond, Bart Van Wijmeersch, Eric Berger, Aurélie Ruet, Serkan Ozakbas, Jonathan Ciron, Tünde Csépány, Jean Philippe Camdessanche, Sandra Vukusic, Nicolas Maubeuge, David Laplaud, Cavit Boz, Christine Lebrun, Claudia C. Hilt Christensen, Patrizia Sola, Vahid Shaygannejad, Romain Casey, Murat Terzi, Philippe Cabre, Jérôme De Seze, Abdullatif Al-Khedr, Dana Horakova, Pamela A. McCombe, Daniele Spitaleri, Alexandre Prat, Gilles Edan, Hélène Zéphir, Aude Marousset, Sifat Sharmin, Diana Ferraro, Sara Eichau, Rana Karabudak, Thibault Moreau
Publikováno v:
Multiple Sclerosis and Related Disorders
Multiple Sclerosis and Related Disorders, Elsevier, 2021, 53, pp.103012. ⟨10.1016/j.msard.2021.103012⟩
Andersen, J B, Sharmin, S, Lefort, M, Koch-Henriksen, N, Sellebjerg, F, Sørensen, P S, Hilt Christensen, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Eichau, S, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Skibina, O, Solaro, C, Karabudak, R, Wijmeersch, B V, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, Sèze, J D, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Marousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Leray, E, Laplaud, D A, Butzkueven, H, Kalincik, T, Vukusic, S & Magyari, M 2021, ' The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies ', Multiple Sclerosis and Related Disorders, vol. 53, 103012 . https://doi.org/10.1016/j.msard.2021.103012
Multiple Sclerosis and Related Disorders, 2021, 53, pp.103012. ⟨10.1016/j.msard.2021.103012⟩
Multiple Sclerosis and Related Disorders, Elsevier, 2021, 53, pp.103012. ⟨10.1016/j.msard.2021.103012⟩
Andersen, J B, Sharmin, S, Lefort, M, Koch-Henriksen, N, Sellebjerg, F, Sørensen, P S, Hilt Christensen, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Eichau, S, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Skibina, O, Solaro, C, Karabudak, R, Wijmeersch, B V, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, Sèze, J D, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Marousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Leray, E, Laplaud, D A, Butzkueven, H, Kalincik, T, Vukusic, S & Magyari, M 2021, ' The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies ', Multiple Sclerosis and Related Disorders, vol. 53, 103012 . https://doi.org/10.1016/j.msard.2021.103012
Multiple Sclerosis and Related Disorders, 2021, 53, pp.103012. ⟨10.1016/j.msard.2021.103012⟩
Background: Natalizumab and fingolimod were the first preparations recommended for disease breakthrough in priorly treated relapsing-remitting multiple sclerosis. Of three published head-to-head studies two showed that natalizumab is the more effecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2f97bab4b243371f958204f4a99d850
http://hdl.handle.net/1942/34842
http://hdl.handle.net/1942/34842
